Silence Therapeutics PLC News - SLN

Silence Therapeutics Reports Fourth Quarter and Full Year 2022 Results

Company to host fourth quarter conference call and webcast today at 8 a.m. EDT / 12 p.m. GMT Silence Therapeutics plc, Nasdaq: SLN (“Silence” or...

Silence Therapeutics to Report Fourth Quarter and Full Year 2022 Results on March 15, 2023

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming...

Amended Statement of Ownership (sc 13g/a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange...

Silence Therapeutics to Present at SVB Securities Global Biopharma Conference

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming...

Silence Therapeutics Appoints J.P. Gabriel as Chief Technical Operations Officer

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K...

Silence Therapeutics Provides SLN360 and SLN124 Clinical Program Updates

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming...

Silence Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming...

Chardan Capital Keeps Their Buy Rating on Silence Therapeutics (SLN)

Chardan Capital analyst Keay Nakae maintained a Buy rating on Silence Therapeutics (SLN - Research Report) today and set a price target of $29.00...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM...

Silence Therapeutics Reports Third Quarter 2022 Results

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming...

Silence Therapeutics to Present at Jefferies London Healthcare Conference

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming...

Silence Therapeutics Presents New Analysis from SLN360 Phase 1 Single Dose Study in High Lipoprotein(a) at the American Heart Association (AHA) 2022 Annual Meeting

– Assessment showed participants who received a single dose of SLN360 maintained median reductions over 80% over a five-month period Silence...

Amended Statement of Beneficial Ownership (sc 13d/a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Silence Therapeutics PLC (SLN)

Professional-Grade Tools, for Individual Investors.

SLN News

Silence Therapeutics Reports Fourth Quarter and Full Year 2022 Results

Silence Therapeutics to Report Fourth Quarter and Full Year 2022 Results on March 15, 2023

Amended Statement of Ownership (sc 13g/a)

Silence Therapeutics to Present at SVB Securities Global Biopharma Conference

Silence Therapeutics Appoints J.P. Gabriel as Chief Technical Operations Officer

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Silence Therapeutics Provides SLN360 and SLN124 Clinical Program Updates

Silence Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Chardan Capital Keeps Their Buy Rating on Silence Therapeutics (SLN)

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Silence Therapeutics Reports Third Quarter 2022 Results

Silence Therapeutics to Present at Jefferies London Healthcare Conference

Silence Therapeutics Presents New Analysis from SLN360 Phase 1 Single Dose Study in High Lipoprotein(a) at the American Heart Association (AHA) 2022 Annual Meeting

Amended Statement of Beneficial Ownership (sc 13d/a)

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

SLN Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Silence Therapeutics PLC (SLN) News

Silence Therapeutics PLC (SLN)

Professional-Grade Tools, for Individual Investors.

SLN News

Silence Therapeutics Reports Fourth Quarter and Full Year 2022 Results

Silence Therapeutics to Report Fourth Quarter and Full Year 2022 Results on March 15, 2023

Amended Statement of Ownership (sc 13g/a)

Silence Therapeutics to Present at SVB Securities Global Biopharma Conference

Silence Therapeutics Appoints J.P. Gabriel as Chief Technical Operations Officer

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Silence Therapeutics Provides SLN360 and SLN124 Clinical Program Updates

Silence Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Chardan Capital Keeps Their Buy Rating on Silence Therapeutics (SLN)

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Silence Therapeutics Reports Third Quarter 2022 Results

Silence Therapeutics to Present at Jefferies London Healthcare Conference

Silence Therapeutics Presents New Analysis from SLN360 Phase 1 Single Dose Study in High Lipoprotein(a) at the American Heart Association (AHA) 2022 Annual Meeting

Amended Statement of Beneficial Ownership (sc 13d/a)

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

SLN Discussion

Your Recent History